Investment Analysts’ Downgrades for December 2nd (ANAB, BLCO, BXSL, GKOS, KSS, MBGYY, MKL, NU, NVRO, PPRUY)

Investment Analysts’ downgrades for Monday, December 2nd:

AnaptysBio (NASDAQ:ANAB) was downgraded by analysts at BTIG Research from a buy rating to a neutral rating.

Bausch + Lomb (NYSE:BLCO) was downgraded by analysts at Morgan Stanley from an overweight rating to an equal weight rating. The firm currently has $19.00 target price on the stock.

Blackstone Secured Lending Fund (NYSE:BXSL) was downgraded by analysts at Wells Fargo & Company from an overweight rating to an equal weight rating. They currently have $29.00 price target on the stock.

Glaukos (NYSE:GKOS) was downgraded by analysts at Morgan Stanley from an equal weight rating to an underweight rating. They currently have $120.00 price target on the stock.

Kohl’s (NYSE:KSS) was downgraded by analysts at Guggenheim from a buy rating to a neutral rating.

Mercedes-Benz Group (OTCMKTS:MBGYY) was downgraded by analysts at Barclays PLC from an equal weight rating to an underweight rating.

Markel Group (NYSE:MKL) was downgraded by analysts at TD Cowen from a buy rating to a hold rating. They currently have $1,836.00 price target on the stock, down from their previous price target of $1,986.00.

NU (NYSE:NU) was downgraded by analysts at Citigroup Inc. from a neutral rating to a sell rating. They currently have $11.00 target price on the stock, down from their previous target price of $14.60.

Nevro (NYSE:NVRO) was downgraded by analysts at Morgan Stanley from an equal weight rating to an underweight rating. Morgan Stanley currently has $4.00 price target on the stock, down from their previous price target of $9.00.

Kering (OTCMKTS:PPRUY) was downgraded by analysts at JPMorgan Chase & Co. from a neutral rating to an underweight rating.

Poseida Therapeutics (NASDAQ:PSTX) was downgraded by analysts at Piper Sandler from an overweight rating to a neutral rating. They currently have $10.00 target price on the stock.

Upstart (NASDAQ:UPST) was downgraded by analysts at JPMorgan Chase & Co. from a neutral rating to an underweight rating. The firm currently has $57.00 target price on the stock, up from their previous target price of $45.00.